

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231-1981 U.S. PTO

Sir:

03/27/01

Atty. Dkt.: CL001188

Date: March 27, 2001

Attached for filing is the patent application of:

Inventor: YE et al

Entitled: **ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID
MOLECULES ENCODING THESE HUMAN RAS-LIKE
PROTEINS, AND USES THEREOF**JC929 U.S. PTO
09/817198
03/27/01

and including attachments as noted below:

Declaration, Abstract
 71 pages of specification; Sequence Listing and claims (including 23 numbered claims), and
 19 sheets of accompanying drawing/s.
 Record & return the attached assignment to the undersigned.
 Priority is hereby claimed under 35 U.S.C 119 based on the following foreign applications, the entire content of which is hereby incorporated by reference in this application:

Application Number	Country	Day/Month/Year Filed
--------------------	---------	----------------------

, respectively.

Certified copy(ies) of foreign application(s) is/are attached.
 Please amend the specification by inserting before the first line --This is a _____ of PCT application _____, filed _____, the entire content of which is hereby incorporated by reference in this application.--
 Priority is hereby claimed under 35 U.S.C 120/365 based on the following prior PCT applications designating the U.S., the entire content of which is hereby incorporated by reference in this application:

Application Number	Country	Day/Month/Year Filed
--------------------	---------	----------------------

This application is based on the following prior provisional application(s):

Application No.	Filing Date
-----------------	-------------

respectively, the entire content of which is hereby incorporated by reference in this application, and priority is hereby claimed therefrom.

Please amend the specification by inserting before the first line: --This application claims the benefit of U.S. Provisional Application No. _____, filed _____, the entire content of which is hereby incorporated by reference in this application.--

Verified Statement attached establishing "small entity" status (Rules 9 & 27)

The Examiner's attention is directed to the prior art cited in the parent application by applicant and/or Examiner for the reasons stated therein.

Preliminary amendment to claims (attached hereto), to be entered before calculation of the fee below.

 Also attached: **Sub of Computer Readable Sequence Listing Diskette****FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITHE CANCELED**


Basic Filing Fee		\$ 710.00	
Total effective claims 23 - 20 (at least 20) =	3	x \$ 18.00	\$ 54.00
Independent claims 6 - 3 (at least 3) =	3	x \$ 80.00	\$ 240.00
If any proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)			\$ 0.00
	SUBTOTAL	\$ 1004.00	
If "small entity," then enter half (1/2) of subtotal and subtract		\$ (0.00)	
	SECOND SUBTOTAL	\$ 1004.00	
Assignment Recording Fee (\$40.00)		\$ 0.00	
	TOTAL FEE CHARGED TO DEPOSIT ACCOUNT	\$ 1,004.00	

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 50-0970. A duplicate copy of this sheet is attached.

CELERA Genomics Corporation
 45 West Gude Drive, C2-4#20
 Rockville, MD 20850
 Telephone # 240-453-3067
 JDK:pdc

CELERA GENOMICS C rporation
 By Atty: Justin D. Karjala, Reg. No. 43,704

Signature: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:YE et al

JC929 U.S. PTO
09/817198
03/27/01



Art Unit:

Serial No. To Be Assigned

Examiner:

Filed: March 27, 2001

Atty. Docket: CL001188

For: ISOLATED HUMAN RAS-LIKE
PROTEINS, NUCLEIC ACID MOLECULES
ENCODING THESE HUMAN RAS-LIKE
PROTEINS, AND USES THEREOF

**SUBMISSION OF SEQUENCE LISTING
UNDER 37 C.F.R. § 1.821(a)**

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.821(a), applicants submit the Sequence Listing,
including the paper copy of the Sequence Listing and the computer readable copy of the
Sequence Listing.

In the Specification:

The Sequence Listing is provided on pages 55-66 of the specification in the
above-identified application.

REMARKS

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application complies with the Sequence Listing requirements and is now in condition for processing.

Respectfully submitted,

CELERA GENOMICS

By: 
Justin D. Karjala
Reg. No. 43,704

Date: March 27, 2001

Celera Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3067
Fax: 240-453-3084